Aim: To evaluate and correlate the epidermal growth factor receptor (EGFR) expression in oral squamous cell carcinomas (OSCC) patients with metastasis and without metastasis. Materials and methods: The study comprised of 40 samples, 20 cases of metastatic and 20 nonmetastatic OSCC. All the cases were immunostained for EGFR antibody. Epidermal growth factor receptor stained sections were evaluated for staining intensity and distribution. The differences between the groups were statistically analyzed using Chi-square test. Results: Immunoexpression of EGFR in OSCC was 100% among the study groups, where metastatic group showed an increased positive expression comparing to nonmetastatic OSCC that show statistically significance among the study groups. Conclusion: Expression of EGFR can be used as reliable biomarker for prognosis which can be employed in the prediction of the survival of the patient with OSCC. Clinical significance: Since we are in the theragnostic era, evaluating and quantifying the expression of EGFR in OSCC patient will definitely pave a way in targeted drug therapy and personalized medicine for the diseased.
Sharma S, Satyanarayana L, Asthana S, et al. Oral cancer statistics in India on the basis of first report of 29 population-based cancer registries. J Oral Maxillofac Pathol 2018;22(1):18–26.
Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol 2015;8(9): 11884–11894.
Murugesan A, Sabarinath, Sundharam S. Awareness of oral cancer among medical students in Chennai. J Med Radiol Pathol Surg 2016;2:18–22. DOI: 10.15713/ins.jmrps.58.
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492.
Sekar B, Saranyan R, Madhavan Nirmal R, et al. Tumour microenvironment-a neighbourhood. J Adv Med Dent Sci Res 2018;6(8):25–27.
Boxberg M, Leising L, Steiger K, et al. Composition and clinical impact of the immunologic microenvironment in oral squamous cell carcinoma. J Immunol 2019;202(1):278–291. DOI: 10.4049/jimmunol.1800242.
Srichinthu KK, Raveendran AP, Tamilthangam P, et al. Molecular pathogenesis and diagnostic imaging of metastatic jaws. J Pharm Bioallied Sci 2017;9(Suppl 1):S15–S22. DOI: 10.4103/jpbs.JPBS_138_17.
Irani S. Distant metastasis from oral cancer: A review and molecular biologic aspects. J Int Soc Prev Community Dent 2016;6(4):265–271. DOI: 10.4103/2231-0762.186805.
Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008;65(10):1566–1584. DOI: 10.1007/s00018-008-7440-8.
Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19(56):6550–6565. DOI: 10.1038/sj.onc.1204082.
Sasaki T, Hiroki K, Yamashita Y. The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Biomed Res Int 2013;2013:546318. DOI: 10.1155/2013/546318.
Sarkis SA, Abdullah BH, Abdul Majeed BA, et al. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol 2010;2:13. DOI: 10.1186/1758-3284-2-13.
Sasahira T, Kirita T. Hallmarks of cancer-related newly prognostic factors of oral squamous cell carcinoma. Int J Mol Sci 2018;19(8):2413. DOI: 10.3390/ijms19082413.
Christensen ME, Therkildsen MH, Hansen BL, et al. Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinoma. Eur Arch Otorhinolaryngol 1992;249(5):243–247. DOI: 10.1007/BF00714485.
Kręcicki T, Jeleń M, Zalesska-Kręcicka M, et al. Epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and Ki-67 antigen in laryngeal epithelial lesions. Oral Oncol 1999;35(2):180–186. DOI: 10.1016/S1368-8375(98)00100-6.
Fong Y, Chou SJ, Hung KF, et al. An investigation of the differential expression of Her2/neu gene expression in normal oralmucosa, epithelial dysplasia, and oral squamous cell carcinoma in Taiwan. J Chin Med Assoc 2008;71(3):123–127. DOI: 10.1016/S1726-4901(08)70003-0.
Hiraishi Y, Wada T, Nakatani K, et al. Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas. Pathol Oncol Res 2006;12(2):87–91. DOI: 10.1007/BF02893450.
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67(6):2643–2648. DOI: 10.1158/0008-5472.CAN-06-4158.
Kimura I, Kitahara H, Ooi K, et al. Loss of epidermal growth factor receptor expression in oral squamous cell carcinoma is associated with invasiveness and epithelial-mesenchymal transition. Oncol Lett 2016;11(1):201–207. DOI: 10.3892/ol.2015.3833.
Huang SF, Chien HT, Cheng SD, et al. EGFR copy number alterations in primary tumors, metastatic lymph nodes, and recurrent and multiple primary tumors in oral cavity squamous cell carcinoma. BMC Cancer 2017;17(1):592. DOI: 10.1186/s12885-017-3586-9.
Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers 2017;9(5):52. DOI: 10.3390/cancers9050052.